Alteogen, a biotech platform company, is set to present findings from animal trials on a high-volume subcutaneous injection device at an international conference this May, in collaboration with global medical device giant Becton Dickinson (BD).
This breakthrough in drug delivery technology is seen as a critical response to the growing demand for high-dose biopharmaceuticals, underscoring the strategic alliance between the two firms.
Industry sources revealed on Monday that Alteogen will participate in the PDA Miniverse: Medical Devices, Combination Products and Connected Health Conference 2026, scheduled for May 21-22 in Dublin, Ireland.
This prestigious conference brings together global leaders in injectable drugs, drug delivery systems, and combination products, with a spotlight on large-volume drug administration and patient-centric treatment technologies. Alteogen’s Chief Executive Officer (CEO), Jeon Tae-yeon, will personally attend to present the experimental results alongside BD representatives.
The presentation, titled, Assessment of 10mL In Vivo Injections With and Without Hyaluronidase ─ A BD and Alteogen Collaboration, will showcase animal trial results evaluating injection speed, duration, and site differences for the large-volume (10mL) subcutaneous injection device utilizing Alteogen’s hyaluronidase-based ALT-B4.
Notably, the study demonstrates that combining ALT-B4 with a wearable device significantly enhances the efficiency of subcutaneous delivery for large-volume drugs, potentially revolutionizing the administration of high-dose biopharmaceuticals.
Becton Dickinson, a frontrunner in the global medical device industry, boasts an extensive portfolio of drug delivery solutions including prefilled syringes, auto-injectors, and wearable injectors, with a strong competitive edge in developing combination products.
Jeon, Alteogen’s CEO, commented that Becton Dickinson is the world’s leading drug delivery device company, with unparalleled technological prowess and expertise. It believes this presentation will highlight the technological synergy between the companies and showcase the competitive advantage in the large-volume subcutaneous injection market.
He further noted that as high-dose biopharmaceuticals like monoclonal antibodies and bispecific antibodies become more prevalent, the demand for effective delivery technologies is skyrocketing. They’re confident in our ability to offer subcutaneous injection solutions that integrate devices for both the current license partners and potential future collaborators.
In related news, Alteogen has inked licensing agreements with eight partners keen on developing subcutaneous injection formulations using the Hybrozyme platform. Following a technology transfer deal with pharmaceutical giant GSK in January, the company further expanded its reach by partnering with Biogen in March.